文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 基础医学 > Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
侵权投诉

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

The new england journal of medicine

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder, M.D., Vladimir Makarov, M.D., Taha Merghoub, Ph.D., Jianda Yuan, M.D., Ph.D., Jesse M. Zaretsky, B.S., Alexis Desrichard, Ph.D., Logan A. Walsh, Ph.D., Michael A. Postow, M.D., Phillip Wong, Ph.D., Teresa S. Ho, B.S., Travis J. Hollmann, M.D., Ph.D., Cameron Bruggeman, M.A.,

Kasthuri Kannan, Ph.D., Yanyun Li, M.D., Ph.D., Ceyhan Elipenahli, B.S., Cailian Liu, M.D., Christopher T. Harbison, Ph.D., Lisu Wang, M.D.,

Antoni Ribas, M.D., Ph.D., Jedd D. Wolchok, M.D., Ph.D.,

and Timothy A. Chan, M.D., Ph.D.

ABSTRACT

Background

From the Department of Medicine (A.S., T.M., M.A.P., J.D.W.), Human Oncology and Pathogenesis Program (A.S., V.M., A.D., L.A.W., K.K., T.A.C.), Swim across America–Ludwig Collaborative Research Laboratory (T.M., Y.L., C.E., C.L., J.D.W.), Department of Radiation Oncology (T.A.C.), Department of Pathology (T.J.H.), and Immunology Program, Lud-wig Center for Cancer Immunotherapy (J.Y., P.W., T.S.H., J.D.W.), Memorial Sloan Kettering Cancer Center; Weill Cor-nell Medical College (A.S., M.A.P., J.D.W., T.A.C.); and Department of Mathemat-ics, Columbia University (C.B.) — all in New York; the Department of Molecular and Medical Pharmacology (J.M.Z., A.R.) and the Department of Medicine, Divi-sion of Hematology–Oncology, Jonsson Comprehensive Cancer Center (A.R.), University of California, Los Angeles, Los Angeles; and Bristol-Myers Squibb, Princeton, NJ (C.T.H., L.W.). Address re-print requests to Dr. Chan at the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave., Box 20, New York, NY 10065, or at chant@mskcc.org; or to Dr. Wolchok at the Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, or at wolchokj@mskcc.org.Drs. Snyder, Makarov, Merghoub, and Yuan and Drs. Wolchok and Chan contributed equally to this article.

This article was published on November 19, 2014, and updated on November 21, 2014, at NEJM.org.

DOI: 10.1056/NEJMoa1406498

Copyright © 2014 Massachusetts Medical Society.

Immune checkpoint inhibitors are effective cancer treatments, but molecular deter-minants of clinical benefit are unknown. Ipilimumab and tremelimumab are anti-bodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti–CTLA-4 treatment prolongs overall survival in patients with melanoma. CTLA-4 blockade activates T cells and enables them to destroy tumor cells.

Methods

We obtained tumor tissue from patients with melanoma who were treated with ipilimumab or tremelimumab. Whole-exome sequencing was performed on tumors and matched blood samples. Somatic mutations and candidate neoantigens gener-ated from these mutations were characterized. Neoantigen peptides were tested for the ability to activate lymphocytes from ipilimumab-treated patients.

Results

Malignant melanoma exomes from 64 patients treated with CTLA-4 blockade were characterized with the use of massively parallel sequencing. A discovery set con-sisted of 11 patients who derived a long-term clinical benefit and 14 patients who derived a minimal benefit or no benefit. Mutational load was associated with the degree of clinical benefit (P = 0.01) but alone was not sufficient to predict benefit. Using genomewide somatic neoepitope analysis and patient-specific HLA typing, we identified candidate tumor neoantigens for each patient. We elucidated a neo-antigen landscape that is specifically present in tumors with a strong response to CTLA-4 blockade. We validated this signature in a second set of 39 patients with melanoma who were treated with anti–CTLA-4 antibodies. Predicted neoantigens activated T cells from the patients treated with ipilimumab.

Conclusions

These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti–CTLA-4 agents are being considered. (Funded by the Frederick Adler Fund and others.)

n engl j med nejm.org

1

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

第1页

你可能喜欢

热门文档

相关文档

  • PD-1-PD-1L在免疫耐受

    [43] attributed this hindered immune response to ...Antibody-mediated blockade of PDL1 but not PD-L...Genetic progress towards the molecular basis of ...

  • NEJMoa1200694

    genetic and epigenetic changes found in all ...clinical data show that antibody blockade of these...patients with melanoma achieved a complete response...

  • PD-1-PD-1L在免疫耐受

    [43] attributed this hindered immune response to ...Antibody-mediated blockade of PDL1 but not PD-L...Genetic progress towards the molecular basis of ...

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email